TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07830719: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study of YMI024 to Assess Efficacy in Reducing Inflammatory Markers, Safety, and Tolerability in Adults With Stable Coro

Sponsor: Novartis Pharmaceuticals · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 180 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$6,640,000

Rescue Site Savings

+$4,382,400

Unlock Full NCT07830719 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07830719 Rescue Dossier →